All come back normal
3.7 Cancer risk by individual GLP-1 RA compound When stratified by individual GLP-1 RAs, liraglutide and semaglutide were associated with reduced risk of gastrointestinal cancers (HR 0.77 and 0.79, respectively), while dulaglutide showed a neutral association (HR 0.91, 95% CI: 0.721.14)
They should mainly be used as second-line therapy as add on to metformin in patients with type 2 diabetes who have no pre-existing cardiovascular disease and have a therapeutic goal to avoid hypoglycaemic events
Benefits Include: Reduced cravings Smaller portion sizes Improved satiety Better blood sugar control Consistent calorie reduction Clinical research published by the National Institutes of Health (NIH) and Clinical Trials demonstrates that Semaglutide-based therapies can support meaningful weight reduction when combined with lifestyle changes
154 The same researchers conducted a four-month crossover trial with 20 perimenopausal women (each participant receiving two months of maca, at a dose of 1 gram twice daily, and two months of placebo, in random order) and found menopausal symptoms, such as hot flashes, night sweats, sleep problems, nervousness, depression, and heart palpitations, and improved parameters of metabolism were reduced during maca treatment
Exosome-coated tPA/catalase nanoformulation for thrombolytic therapy
